Nanobiotix: first patient randomized in the United States
Radiation-activated NBTXR3 will be evaluated alone or in combination with cetuxima, in elderly patients with locally advanced head and neck cancer who are not eligible for platinum-based chemotherapy.
With the addition of the USA to Europe and Asia, patients are now being randomized in all major regions of the study. Futility analysis is scheduled for the second half of 2023, and interim data for the second half of 2024.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction